Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Central European Advanced Therapy and Immunotherapy Centre (CREATIC)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Czechia,Germany,Denmark
Call: Teaming for Excellence (HORIZON-WIDERA-2022-ACCESS-01-two-stage, 2022)
Start date: 2023-09-01
End date: 2029-08-31
Duration (months): 72.0
Total project cost (EUR): 14999906.25
EU funding (EUR): 14999906.25
Participants: 4
Project status: SIGNED

Progress in biomedical science enables scientists to use a whole new toolbox to treat significant groups of diseases, such as inherited rare diseases or diverse rare cancers. Advanced therapy medicinal products (ATMPs) apply recent advances in genomics, cell biology and/or gene editing to deliver truly personalized curative options. The project proposes to establish flagship ATMP-focused facility on the margin of academia and clinics: Central European Advanced Therapy and Immunotherapy Centre (CREATIC) at the Masaryk University (MU) in Brno, Czech Republic. MU will team up with the leading European research institutions: (1) Fraunhofer Institute for Cell Therapy and Immunology IZI, (2) Leipzig University, which together forms a significant cluster of research excellence in research, development and training in the fields of gene and cell therapies and (3) Copenhagen University with unique expertise in biomedical innovation law, intellectual property, biomedical ethics, privacy and regulatory framework, and health technology assessment. Combining STM and SSH disciplines the project will allow for (i) fundamental expansion of the scope of the R&I activities of all partners to build multidisciplinary excellence facilitating the delivery of ATMPs to patients who need them; (ii) establishment of the high level of decision-making autonomy for the CREATIC, which will allow significant organizational and management changes creating spirit and conditions for cutting-edge research and innovation in the Centre, and (iii) strengthen the smart specialization of the Czech Republic (RIS3 CZ 2021-2027) in the domain of Advanced medicine and drugs through the involvement of actors from the academic, public, private and societal sector. Our approach reflects research priorities and societal challenges outlined in the Pharmaceutical Strategy for Europe, which proposes ‘bedside’ manufacture of highly individualised medicines as a future trend in treating rare diseases with ATMPs.

Keywords: advanced therapy medicinal products,living drugs,bedside manufacture,personalised medicine,precision genomics,multidisciplinary approach,research management,education
TOWARDS A SUSTAINABLE EU-LAC PARTNERSHIP IN RESEARCH INFRASTRUCTURES (EU-LAC ResInfra Plus)

Framework: Horizon Europe — Excellent Science
Programme: Research infrastructures
Theme: Research infrastructures
Destination: Development and infrastructures
Action type: Coordination and support actions
Countries involved: Spain,United Kingdom,Costa Rica,Colombia,Cuba,Chile,Peru,Argentina,Uruguay,Germany,Portugal,Italy,Finland,Romania,Brazil
Call: Strengthen the bilateral cooperation on research infrastructures with Latin America (HORIZON-INFRA-2023-DEV-01, 2023)
Start date: 2024-01-01
End date: 2025-12-31
Duration (months): 24.0
Total project cost (EUR): 768908.27
EU funding (EUR): 749943.98
Participants: 20
Project status: SIGNED

H2020 EU-LAC ResInfra project served to boost the bi-regional collaboration on research infrastructures (RIs) between European Union (EU) and Latin America and Caribbean (LAC) countries. To this aim a variety of different activities were developed that have proven the importance of RIs as a key pillar in boosting the R&D activities between regions and the need to maintain a sustainable collaboration at governmental level. Despite the success of the results of EU-LAC ResInfra Project, there is still work to do in order to have a solid and sustainable framework of cooperation to enhance the bi-regional collaboration on research infrastructures. Latin America and the Caribbean has a unique landscape of natural laboratories that can provide comparative advantages to host the development of RI’s, as well as high impact science on specific thematic areas that are a priority in both regions. It has been deemed necessary to increase the visibility of both EU and LAC RI models and characteristics to advance in a greater collaboration for a common roadmapping exercise, agreements in long term funding, transnational access, capacity building and mutual openness for the development of a RIs common area. EU-LAC ResInfra Plus has brought together a wide and comprehensive consortium of 20 crucial partners from the EU and LAC countries. The project includes a balanced mix of governmental representatives responsible of the development of RIs policies at national level, RTD funding agencies from EU countries (Finland, Germany, Italy, Portugal, Romania, and Spain) and LAC countries (Argentina, Brazil, Colombia, Costa Rica, Cuba, Chile, Peru and Uruguay,) as well as a consolidated group of European RIs: Instruct-ERIC, LifeWatch-ERIC, RICAP and MIRRI-ERIC. This broad spectrum of partners gathers to all the RIs stakeholders to ensure that the project activities and outputs serve to strengthening the bi-regional collaboration.

Keywords: eu lac resinfra eu lac cooperation research infrastructure strategic roadmap bi regional collaboration capacity building bottlenecks best practices policy dialogue
Graphene: Europe in the Lead Coordination and Support Action (GrapheneEU)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Digital
Destination: Digital & Emerging Technologies for Competitiveness and Fit for the Green Deal
Action type: Coordination and support actions
Countries involved: Sweden,France,Germany,United Kingdom
Call: Supporting the coordination of the Graphene Flagship projects (CSA) (HORIZON-CL4-2022-DIGITAL-EMERGING-02, 2022)
Start date: 2023-10-01
End date: 2026-09-30
Duration (months): 36.0
Total project cost (EUR): 2914230.0
EU funding (EUR): 2914230.0
Participants: 6
Project status: SIGNED

The Graphene Flagship (GF) initiative aims at advancing Europe’s strategic autonomy in technologies that rely on graphene and other 2D materials and sustaining the first-mover advantage that Europe has obtained through earlier investments. This overarching goal will be pursued by a number of graphene and 2D materials (2DM) related actions – Research and Innovation Actions (RIAs) and Innovation Actions (IAs) – in collaboration with activities funded by the EU member states and associated countries. The overall coherence of the GF initiative is guaranteed by a Coordination and Support Action (CSA) that allows the separate actions to exploit synergies in their scientific and technological activities and work more efficiently by utilising common services and support functions. GrapheneEU builds upon the extensive experience and expertise of a consortium that has been responsible for the central support and coordination functions of the Graphene Flagship during the FP7 and Horizon 2020 phases and therefore has access to the broad network of researchers and organisations which will participate in the GF initiative. GrapheneEU will ensure a strong and coherent initiative by providing key support functions in coordination and governance, industrialisation, dissemination, and alignment, enabling the participating projects to identify and utilise synergies in their work, share best practices, and promote interactions with relevant national and regional initiatives. GrapheneEU will help secure a sustained European leadership in 2DM by capitalising on the investments in the Graphene Flagship from the FP7 and Horizon 2020 phases and fostering and facilitating the work to be continued during Horizon Europe.

Keywords: graphene 2d materials coherence common services continuation key support functions governance industrialisation support standardisation roadmapping coordination alignment dissemination
Pre-Comercial Procurement of innovative and sustainable solutions to Treat HEalthcaRE System wAstewater (THERESA PCP)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Ensuring access to innovative, sustainable and high-quality health-care
Action type: Pre-Commercial Procurement
Countries involved: Spain,Greece,Netherlands,Poland,Estonia,Belgium
Call: Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems (HORIZON-HLTH-2024-CARE-14, 2024)
Start date: 2025-09-01
End date: 2029-08-31
Duration (months): 48.0
Total project cost (EUR): 5287206.25
EU funding (EUR): 5287206.25
Participants: 17
Project status: SIGNED

Hospital wastewater (HWW) poses a significant environmental and health risk due to the presence of pharmaceuticals, pathogens, and other hazardous substances that are administered in healthcare institutions. Unfortunately, current urban wastewater treatment (WWT) plants are not capable of effectively removing many of the pollutants generated by hospitals. As a result, these contaminants reach and accumulate in natural water bodies, threatening ecosystems and biodiversity, and public health through the contamination of drinking water or food. In addition, public health is also menaced by HWW as it contains important amounts of antibiotic-resistant microorganisms and genes. In fact, Antimicrobial Resistance (AMR) is one of the greatest health threats of our times. While most common medicines are consumed in households, specialized drugs such as cytostatic drugs, some antibiotics, or X-ray contrast agents are mainly distributed in hospitals. Furthermore, HWW is a hotspot for the transmission of antibiotic-resistant bacteria (ARB) and antibiotic-resistant genes (ARG). To reduce the risk associated to these contaminants, it is key to remove them as close to their source as possible, and before they are discharged to the municipal water network. Despite the existence of different technologies that efficiently remove contaminants from HWW, currently, there is no single process that can be used for the comprehensive treatment of HWW regarding the elimination of a mix of pollutants to a high degree. Moreover, technology may be further developed to be more efficient, environmentally sustainable, and cost-effective for hospitals. In this context, the main objective of THERESA PCP is to launch a pre-commercial procurement process (PCP) based on the development of an environmentally sustainable on-site system to decontaminate HWW, being capable of effectively removing, among other contaminants, cytostatic drugs, X-ray contrast agents, antibiotics, ARB and ARG, from HWW.

Keywords: hospital wastewater,wastewater treatment,antibiotics,x ray contrast agents,cytostatics,antimicrobial resistance,antibiotic resistant bacteria,antibiotic resistant genes,green deal,one health
Shedding light on the key molecular determinants regulating 3D diffusion and activity of antimicrobials in bacterial biofilms. (BIOinFILM)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Portugal,Italy
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2025-09-01
End date: 2027-08-31
Duration (months): 24.0
Total project cost (EUR): 156778.56
EU funding (EUR): 156778.56
Participants: 3
Project status: SIGNED

Bacterial biofilms are associated with approximately 1.7 million hospital-acquired infections annually in the United States, incurring an annual economic burden of about 11 billion dollars. The role of biofilms in antimicrobial resistance (AMR) is highly complex and may significantly drive resistance. Biofilms can act as a diffusion-limiting barrier against various antimicrobials resulting in limited drug access into the bacterial cells. The evaluation and quantification of biofilm diffusion is essential since it is a poorly researched topic, and the matrix properties are necessary to define the bacterial populations within the biofilm. In this project, an antimicrobial peptide (AMP) will be used as a model molecule because AMPs are known for their activity against biofilms and have been considered promising antibiofilm agents. The vCPP2319, a peptide developed by the Instituto de Medicina Molecular team (iMM), was chosen for the project as a diffusion model reporter. The research plan is organized into three scientific Work Packages (WP). WP1 aims at studying the fundamental properties of biofilms, whereas WP2 and WP3 aim at studies using vCPP2319 and the library of its variants, respectively, as molecular models to elucidate their diffusion-related properties in biofilms and correlate antibiofilm activity with the metabolic status of biofilm-embedded bacterial cells. The project will use two reference and two clinical strains of Staphylococcus aureus and Klebsiella pneumoniae as models. These bacterial species will be selected because they are clinically relevant pathogens frequently associated with biofilm infections. Overall, the project's relevance is overcoming the gap of knowledge associated with molecular diffusion in biofilms and relating the diffusion of antimicrobials within biofilms with their activity. This will enable the future development of innovative chemotherapies to fight against biofilm-related infections.

Keywords: bacterial biofilms,molecular diffusion,antimicrobials,peptide
Early life imprinting of B cell memory and its role in adult immunity (ELO-B-Memory)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Immunity, Infection and I mmunotherapy
Panel description: The immune system , related disorders  and their mechanisms , biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases , innovative imm unological tools and approaches , including  therapies
Countries involved: Sweden
Call: ERC CONSOLIDATOR GRANTS (ERC-2023-COG, 2023)
Start date: 2024-06-01
End date: 2029-05-31
Duration (months): 60.0
Total project cost (EUR): 1999983.0
EU funding (EUR): 1999983.0
Participants: 1
Project status: SIGNED

This proposal addresses the combined role of early life derived B cells in the adult immune system. Neonatal immune imprinting is now well-established concept. It emphasizes the importance of the early life window to establish host-microbial mutualism and the set-point for immune responsiveness later in life. However, the cellular and molecular mechanisms underlying this immune programming are not well understood. Despite the ability of B cells to integrate and store complex immunological memory for a lifetime, surprisingly little is known about its ability to confer the longitudinal effects of neonatal microbial instruction. By time-stamping B cells that arise early in life, my research team resolved a self-sustaining network of IgM and IgA B and plasma cells that carry memory of neonatal exposure. Such early life origin B (ELO-B) cells are unevenly distributed among immunophenotypically and anatomically defined B cell subsets and make up a substantial portion of the adult B cell pool in unimmunized mice. These findings reveal pervasive neonatal antigenic imprinting of the adult B cell compartment, challenging the assumption that the adaptive immune system is naïve in the absence of deliberate immunization. With this understanding arises an urgent need to dissect the formation and function of ELO-B cell memory and their lasting impact on host protection and long-term homeostasis. To this end, we have built an unprecedented genetic toolkit leveraging the power of our time-stamping approach, to track and manipulate ELO-B cell responses without perturbing adul Overarching hypothesis: ELO-B cells uniquely imprinted by developmental and microbial determinants early in life shape the trajectory of adult immune responses in health and disease. Aim 1. Dissecting the formation of a complex ELO-B cell layer. Aim 2. Tracing ELO-B cell derived antibodies and their contribution to adult B cell responses. Aim 3. Defining the role for ELO-B cells in immunological tolerance.

Keywords: neonatal immune imprinting,neonatal b cell memory,b 1 cells,il 10,iga,microbiota,lineage tracing
Wheat diversity and domestication in volcanic Cappadocia: Exploring human-plant interactions and their ecological contexts at the dawn of agriculture in western Asia (WHEADCAP)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: France,United Kingdom
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-01-05
End date: 2028-01-04
Duration (months): 24.0
Total project cost (EUR): 226420.56
EU funding (EUR): 226420.56
Participants: 2
Project status: SIGNED

Early plant management and domestication have shaped the history of humanity and the evolution of socio-economic systems. Domestication processes, involving variable rates of selection over several millennia across different geographies in western Asia, resulted in complex phenotypical and genetic alterations in crop plants, while influencing new economic practices among human populations. Yet, the data for the nature of early agriculture and human-derived dynamics entangled in the selection of domestication traits is still limited. What practices did early management systems involve and how did these influence crop diversity and the protracted, non-linear selection of traits? To find answers, the WHEADCAP project focuses on one of the oldest groups of crop plants, wheats (Triticum spp.), and the archaeobotanical assemblages from three early Neolithic communities (9th-8th millennium cal. BCE) in volcanic Cappadocia, Central Anatolia (Türkiye). A rich phenotypic diversity characterises these assemblages, including the globally oldest known in situ domestication process of several wheat species. The project aims to integrate two cutting-edge methodologies to detect patterns conventional approaches cannot unveil. First, WHEADCAP will develop new Geometric Morphometric models to disentangle the high taxonomic and phenotypic diversity within the early wheat populations and to reconstruct the evolution of domesticated forms of wheats in a specific geographical context. Functional Weed Ecology will then be applied at the Secondment to assess past crop growing conditions and management practices, revealing the ecological context of the domestication and selection processes. While reshaping our perspectives on agricultural origins and contributing to my professional career through new scientific skills, the project will also provide novel and widely applicable models to study human-plant interactions and domestication at the onset of agriculture in western Asia and beyond.

Keywords: archaeobotany,west asian neolithic,wheat diversity and domestication,geometric morphometrics,functional weed ecology
Digital optical computing platform for neural networks (DOLORES)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Denmark,Netherlands,Belgium,United Kingdom
Call: EIC Pathfinder Open (HORIZON-EIC-2023-PATHFINDEROPEN-01, 2023)
Start date: 2024-09-01
End date: 2028-08-31
Duration (months): 48.0
Total project cost (EUR): 3015883.75
EU funding (EUR): 3015883.25
Participants: 6
Project status: SIGNED

Artificial Intelligence - humanity’s new frontier - has dramatically progressed during the past decade due to the introduction of deep learning. Deep learning applications usually require vast amounts of computing resources but microelectronics are encountering physically fundamental bottlenecks in speed, energy consumption, heating, and interconnect delay, which can no longer be resolved by scaling. The end of Moore’s law urgently calls for the introduction of new devices, new integration technologies, and new architectures to efficiently accelerate deep learning applications. Recently, optical neural networks (ONNs) based on photonic integrated circuits have shown great potential as an emerging computing architecture beyond von Neumann and Moore to overcome the bottlenecks in their microelectronics counterparts. Yet the ONN concepts and demonstrations so far are encountering severe obstacles such as limited calculation precision, repeatability, scalability, and compatibility with microelectronics. These obstacles are deeply rooted in the analogue computing architecture of the existing ONNs: insufficient signal-to-noise ratio due to accumulated noise and crosstalk in the system. DOLORES aims to explore and develop a radically new digital optical computing platform to create a new class of processors, namely a digital optical neural network (DONN) processor, that is fundamentally different from any ONN scheme and solves the aforementioned obstacles. Integrating the best of photonics and electronics, DOLORES is expected to revolutionize optical computing, and in the long-term vision enable new possibilities that are barely supported by today’s computing hardware. If successful, DOLORES can pave the way for a new era in AI, drastically accelerating neural networks and deep learning applications, which have the potential to transform many sectors of our society, including healthcare, finance, and transportation.

Keywords: optical neural networks,optical computing,cointegration of photonics and electronics